BioLens Raises $55M to Commercialize AI Microscopy Diagnostics and Launches Clinician Beta

AI · 6 min read

BioLens secured $55 million in Series B financing aimed at commercializing its AI-driven microscopy diagnostics platform. The technology automates slide triage, highlights regions of interest, and provides suggested annotations to pathologists to speed throughput.

With the investment, BioLens launched a clinician beta across several academic hospitals to validate clinical workflows and refine model performance in real-world conditions. The company is also preparing regulatory submissions in multiple jurisdictions, focusing on safety and explainability metrics.

Funding will be allocated toward clinical trials, partnerships with digital pathology vendors, and scaling the cloud architecture needed for secure image handling. Early clinical partners reported reductions in review times and improved consistency in routine diagnostic tasks.